#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cryoglobulinaemia Leukocyte adhesion deficiency type I Hypophosphatasia Mantle cell lymphoma stage III Congenital pseudarthrosis Anaplastic large cell lymphoma T- and null-cell types T-cell type acute leukaemia Renal cell carcinoma Hereditary motor and sensory neuropathy Acute lymphocytic leukaemia HER2 mutant non-small cell lung cancer Idiopathic pulmonary fibrosis Chronic lymphocytic leukaemia refractory Thrombocytosis Myelodysplastic syndrome with excess blasts More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia recurrent – Life with Disease Inclusion body myositis – Trials in Disease Gastrointestinal stromal tumour – Treatment Ehlers-Danlos syndrome – Diagnostics Immunodeficiency congenital Short-bowel syndrome – Basic Information IgA nephropathy – Basic Information Bronchiolitis obliterans syndrome – Diagnostics Pemphigoid – Life with Disease Angiosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metoclopramide Hydrochloride Sildenafil Citrate Ict01 Human Immunoglobulin G Alxn1850 Mps-215 Elafibranor Olorofim Phenol, Liquefied Iph6501 CYCLIZINE HYDROCHLORIDE Thalidomide Xaluritamig E2814 Caraway Oil Fludarabine Phosphate ICEF15 Sotorasib Ponatinib Garadacimab More therapies…

    Learn about Your Condition

    Desmoplastic melanoma Neurofibromatosis Kawasaki's disease Erosive oesophagitis Malignant melanoma stage II Post procedural complication Schizophreniform disorder Intestinal obstruction Periodontitis Cancer fatigue HER2 negative breast cancer Netherton's syndrome Pelvic venous thrombosis Anorexia nervosa Autism spectrum disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Leuprorelin
    • Anastrozole
    • Triptorelin
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study of BMS-986340, Nivolumab, and Docetaxel for Adults with Advanced or Metastatic Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Bms-986340
    • Docetaxel
    • Nivolumab
    Germany Italy Spain

  • Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

    Recruiting

    4 1 1
    Investigated Drugs:
    • ARLOCABTAGENE AUTOLEUCEL
    • Lisocabtagene Maraleucel
    • CC-97540
    Austria Belgium Czechia Denmark Finland France +11

  • Study on the Use of Simoctocog Alfa and Emicizumab for Surgery in Patients with Severe Hemophilia A

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Simoctocog Alfa
    Croatia Finland France Germany Italy Spain

  • Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Epirubicin Hydrochloride
    • Dacarbazine
    • Ifosfamide
    Cyprus Czechia Denmark France Germany Italy +4

  • Study of Cetuximab and Avelumab for Patients with Recurrent or Metastatic Head and Neck Cancer with PD-L1 Score 1 or Higher

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    Italy

  • Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Hepatic cirrhosis
    Investigated Drugs:
    • Efruxifermin
    Belgium Denmark France Germany Greece Italy +2

  • Study Comparing FDG-PET/CT and CT for Monitoring Treatment Response in Patients with Metastatic Breast Cancer Using Fludeoxyglucose (18F)

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    Denmark Germany Italy

  • Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    • Endometrial cancer
    • Endometrial cancer recurrent
    Investigated Drugs:
    • Niraparib Tosilate Monohydrate
    • Dostarlimab
    France Italy Spain

  • Study on Buccalin for Preventing Recurrent Lower Respiratory Infections in Adults

    Recruiting

    3 1 1
    Investigated Drugs:
    • Haemophilus Influenzae
    • Staphylococcus Aureus
    • Streptococcus Agalactiae
    Italy
Previous Page
1 … 27 28 29 30 31 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!